A Business at a Glance
0 of 5 daily views used (5 remaining). Sign up free for 10 daily views, or try AAPL for a full preview.
Bausch Health Companies Inc. (“we”, “us”, “our”, the “Company” or “Bausch Health”) is a global, diversified specialty pharmaceutical and medical device company that develops, manufactures and markets, primarily in the therapeutic areas of gastroenterology (“GI”), hepatology, neurology and dermatology, a broad range of branded, generic and branded generic pharmaceuticals, over-the-counter (“OTC”) products and aesthetic medical devices and, through our approximately 88% ownership of Bausch + Lomb Corporation (“Bausch + Lomb” or “B+L”), branded, and branded generic pharmaceuticals, OTC products and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment) in the therapeutic areas of eye health. The Company’s products are marketed directly or indirectly in approximately 90 countries. Our portfolio of products falls into five reportable segments: (i) Salix, (ii) International, (iii) Solta Medical, (iv) Diversified and (v) Bausch + Lomb.
| Metric | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|---|
| Revenue | 10.3B | 10.3B | 9.6B | 8.8B | 8.1B | 8.4B |
| Net Income | 157M | 157M | -46M | -592M | -225M | -948M |
| EPS | $0.42 | $0.42 | $-0.13 | $-1.62 | $-0.62 | $-2.64 |
| Free Cash Flow | 1.0B | 1.0B | 1.3B | 817M | -946M | 1.2B |
| ROIC | 3.7% | 5.6% | 4.5% | 4.8% | 2.3% | 2.1% |
| Gross Margin | 71.3% | 71.3% | 71.6% | 71.2% | 71.5% | 72.0% |
| Debt/Equity | 0.00 | -37.98 | -18.99 | -22.35 | -30.63 | -213.72 |
| Dividends/Share | $0.00 | - | - | - | - | - |
| Operating Income | 1.8B | 1.8B | 1.5B | 963M | 454M | 450M |
| Operating Margin | 17.7% | 17.7% | 16.1% | 11.0% | 5.6% | 5.3% |
| ROE | 0.0% | - | - | - | - | - |
| Shares Outstanding | 374M | 374M | 354M | 365M | 363M | 359M |
Bausch Health Companies Inc. passes 1 of 9 quality checks, indicating weak fundamentals.
Bausch Health Companies Inc. trades at 13.5x trailing earnings, compared to its 15-year median P/E of 10.1x, suggesting it is currently Fair relative to its historical range. On a free-cash-flow basis, the stock trades at 2.1x vs a median of 3.6x. The company's 5-year average ROIC is 3.9% with a gross margin of 71.5%. At current prices, the estimated annualized return to fair value is -6.2%.
Bausch Health Companies Inc. (BHC) has a current P/E ratio of 13.5, compared to its historical median P/E of 10.1. The stock is currently considered Fair based on its historical valuation range.
Bausch Health Companies Inc. (BHC) has a 5-year average return on invested capital (ROIC) of 3.9%. This is below average and may indicate limited pricing power.
Bausch Health Companies Inc. (BHC) has a market capitalization of $2.1B. It is classified as a mid-cap stock.
Bausch Health Companies Inc. (BHC) does not currently pay a regular dividend.
Based on historical P/E analysis, Bausch Health Companies Inc. (BHC) appears fair. The current P/E of 13.5 is 34% above its historical median of 10.1. The estimated fair value CAGR (P/E method) is -30.7%.
Bausch Health Companies Inc. (BHC) operates in the Pharmaceutical Preparations industry, within the Healthcare sector.
Bausch Health Companies Inc. (BHC) reported annual revenue of $10.3 billion in its most recent fiscal year, based on SEC EDGAR filings.
Bausch Health Companies Inc. (BHC) has a net profit margin of 1.5%. This is a modest margin.
Bausch Health Companies Inc. (BHC) generated $1.0 billion in free cash flow in its most recent fiscal year. Positive free cash flow supports dividends, buybacks, and debt reduction.
Bausch Health Companies Inc. (BHC) reported earnings per share (EPS) of $0.42 in its most recent fiscal year.
Bausch Health Companies Inc. (BHC) has a 5-year average gross margin of 71.5%. This high margin suggests strong pricing power and a potential competitive moat.
The Ledger Terminal provides 16 years of financial data for Bausch Health Companies Inc. (BHC), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
Bausch Health Companies Inc. (BHC) has a book value per share of $-1.48, based on its most recent annual SEC filing.